| Literature DB >> 24045337 |
Mary Canavan1, Ciara McCarthy1, Nadia Ben Larbi1, Jennifer K Dowling1, Laura Collins1, Finbarr O'Sullivan2, Grainne Hurley3, Carola Murphy3, Aoife Quinlan3, Gerry Moloney3, Trevor Darby3, John MacSharry3, Hiroyuki Kagechika4, Paul Moynagh5, Silvia Melgar3, Christine E Loscher6.
Abstract
There is now convincing evidence that liver X receptor (LXR) is an important modulator of the inflammatory response; however, its mechanism of action remains unclear. This study aimed to examine the effect of LXR on the IL-12 family of cytokines and examined the mechanism by which LXR exerted this effect. We first demonstrated that activation of murine-derived dendritic cells (DC) with a specific agonist to LXR enhanced expression of LXR following activation with LPS, suggesting a role in inflammation. Furthermore, we showed LXR expression to be increased in vivo in dextrane sulphate sodium-induced colitis. LXR activation also suppressed production of IL-12p40, IL-12p70, IL-27 and IL-23 in murine-derived DC following stimulation with LPS, and specifically targeted the p35, p40 and EBI3 subunits of the IL-12 cytokine family, which are under the control of the NF-κB subunit p50 (NF-κBp50). Finally, we demonstrated that LXR can associate with NF-κBp50 in DC and that LXR activation prevents translocation of the p50 subunit into the nucleus. In summary, our study indicates that LXR can specifically suppress the IL-12 family of cytokines though its association with NF-κBp50 and highlights its potential as a therapeutic target for chronic inflammatory diseases.Entities:
Keywords: Liver X receptor; NF-κB; dendritic cells; interleukin-12
Mesh:
Substances:
Year: 2013 PMID: 24045337 DOI: 10.1177/1753425913501915
Source DB: PubMed Journal: Innate Immun ISSN: 1753-4259 Impact factor: 2.680